The additive effects of NUCB1 with gemcitabine in pancreatic cancer cells suggest that targeting NUCB1, in combination with other current treatment strategies, may improve therapeutic efficacy and clinical outcomes for PDAC patients. This evidence concerns the gene NUCB1 and familial pancreatic carcinoma.